Robin Ali

Biography

 Robin Ali is the Chief Scientific Officer at MeiraGTx.  As chief investigator, Robin established the world’s first clinical trial of gene therapy for retinopathy.  In 2007 he was elected to the UK Academy of Medical Sciences and in 2009 appointed Senior Investigator of The UK National Institute for Health Research.  He is President of the European Society of Gene and Cell Therapy and has served on the advisory boards of several funding bodies including the UK Medical Research Council (Neurosciences and Mental Health Board and the Regenerative Medicine Research Committee), Research to Prevent Blindness USA and Fighting Blindness Ireland, as well as the advisory boards of pharmaceutical and biotech companies, including Alcon/Novartis. Robin Ali obtained his BSc (1988) and PhD in Genetics (1993) at University College London, continued by postdoctoral training at the MRC National Institute for Medical Research and UCL Institute of Ophthalmology and established his laboratory at UCL Institute of Ophthalmology in 1999. Dr. Ali is also a visiting Professor at The Kellogg Eye Center, University of Michigan and Director of the Wolfson Gene Therapy Unit, UCL’s facility for GMP manufacture of viral vectors.

Research Interest

 Research on Gene Therapy